Table 1.
Variable | Value |
---|---|
Age, years | 55.1 ± 8.2 (50–72) |
Sex, male:female | 14:2 |
Course of disease, months | 5.5 (3–18) |
Treg cell number | 1.41 ± 0.3 × 108 |
ISS stage, n (%) | |
I | 3 (18.8) |
II | 7 (43.8) |
II | 6 (37.5) |
CRS stage, n (%) | |
I | 3 (18.8) |
II | 9 (56.3) |
III | 2 (12.5) |
IV | 2 (12.5) |
Complication, n (%) | |
Hyperthermia | 15 (93.8) |
Increase of inflammatory factors | 13 (81.3) |
Muscle pain | 11 (68.8) |
Headache | 9 (56.3) |
Nausea | 8 (50.0) |
Vomiting | 5 (31.3) |
Diarrhea | 3 (18.8) |
Renal impairment | 3 (18.8) |
Liver impairment | 1 (6.3) |
Neurological impairment | 1 (6.3) |
Drugs used before study, n (%) | |
Lenalidomide | 9 (56.3) |
Dexamethasone | 12 (75.0) |
Bortezomib | 7 (43.8) |
Adriamycin | 6 (37.5) |
ISS, International Staging System; CRS cytokine release syndrome.